Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial
- on behalf of the C4591054 Study Group
Research output: Contribution to journal › Article › peer-review
40
!!Link opens in a new tab
Scopus
citations